5-Benzylidene-3-ethyl rhodanine
CAS No. 18331-34-5
5-Benzylidene-3-ethyl rhodanine ( —— )
Catalog No. M20405 CAS No. 18331-34-5
5-Benzylidene-3-ethyl rhodanine(BTR-1) is an active anti-cancer agent. BTR-1 activates apoptosis and induces cell death.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 71 | In Stock |
|
5MG | 110 | In Stock |
|
10MG | 177 | In Stock |
|
25MG | 332 | In Stock |
|
50MG | 478 | In Stock |
|
100MG | 691 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product Name5-Benzylidene-3-ethyl rhodanine
-
NoteResearch use only not for human use.
-
Brief Description5-Benzylidene-3-ethyl rhodanine(BTR-1) is an active anti-cancer agent. BTR-1 activates apoptosis and induces cell death.
-
Description5-Benzylidene-3-ethyl rhodanine(BTR-1) is an active anti-cancer agent. BTR-1 activates apoptosis and induces cell death.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number18331-34-5
-
Formula Weight249.35
-
Molecular FormulaC12H11NOS2
-
Purity>98% (HPLC)
-
SolubilityDMSO:25 mg/mL (100.26 mM)
-
SMILESCCN1C(=S)S\C(C1=O)=C/c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Moorthy B T Ravi S Srivastava M et al. Novel rhodanine derivatives induce growth inhibition followed by apoptosis[J]. Bioorganic and Medicinal Chemistry Letters 2010 20(21):6297-6301.
molnova catalog
related products
-
Etalocib
Etalocib is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase.
-
AP-III-a4 hydrochlor...
AP-III-a4 (ENOblock) hydrochloride is a nonsubstrate analogue enolase inhibitor with an IC50 of 0.576 uM. AP-III-a4 hydrochloride can be used for the research of cancer and diabetic.
-
Pivanex
Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.